Update shared on 24 Nov 2025
Fair value Increased 154%Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.
What's in the News
- Canopy Growth has expanded its Spectrum Therapeutics portfolio with new medical cannabis softgel capsules in Australia, strengthening its presence in the maturing local market (Key Developments).
- Shareholders have approved a potential consolidation of company shares, with implementation at the Board’s discretion within the next 12 months (Key Developments).
- The DOJA facility in Kelowna now operates solely as a medical cultivation site, focusing on small-batch, craft cannabis for Spectrum Therapeutics’ patients, including Canadian veterans (Key Developments).
- Tom Stewart has been appointed as Chief Financial Officer, supporting Canopy Growth’s fiscal year 2026 strategy and further balance sheet improvements (Key Developments).
- The company has completed and filed follow-on equity offerings totaling over $255 million, supporting growth, potential acquisitions, and general corporate purposes (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: Raised from CA$1.30 to CA$3.30, more than doubling the previous estimate.
- Discount Rate: Marginal decrease from 6.13% to 6.12%.
- Revenue Growth: Reduced from 7.8% to 5.4%, reflecting more cautious future sales expectations.
- Net Profit Margin: Improved from 2.92% to 3.08%, indicating an enhanced profitability outlook.
- Future P/E: Increased significantly from 63.8x to 164.3x, suggesting a higher valuation relative to expected earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.